CAR play Cellectis plans listing in U.S.

Cellectis S.A. (Euronext:ALCLS) on Thursday said it plans to list on a U.S. exchange, but has not yet decided on the date, size or terms of the public offering. The immunotherapy play gained EUR 2.90 (15%) to EUR 22 on Friday. It has a market capitalization of EUR 644.6 million ($770.6 million).

The company raised EUR 24.7 million in its Euronext IPO in 2007, pricing its shares at EUR 10.25. When the company set out to raise money early last year, CEO Andre Choulika told BioCentury that U.S. investors were more enthusiastic than their European counterparts. In March 2014, Cellectis closed a EUR 20.5 million ($28.2 million) private placement with OrbiMed Advisors, venBio, Ridgeback Capital, Aquilo Capital and Merlin Nexus (see BioCentury, May 26, 2014). ...